Results 21 to 30 of about 33,637 (157)

Guillain–Barre syndrome after myocardial infarction: a case report and literature review

open access: yesBMC Cardiovascular Disorders, 2023
Background Guillain–Barre syndrome after myocardial infarction occurs infrequently, and its occurrence following percutaneous coronary intervention is extremely rare.
Pu-yuan Wen   +5 more
doaj   +1 more source

Características clínicas y laboratoriales de los diez primeros pacientes con diagnóstico de Guillain-Barré en Piura, 2023

open access: yesAnales de la Facultad de Medicina, 2023
El síndrome de Guillain Barré es una enfermedad derivada del compromiso en las neuronas del sistema nervioso periférico por una respuesta descontrolada del sistema inmune que conduce daño axonal y/o desmielinización.
Luis Pampa-Espinoza   +11 more
doaj   +1 more source

Intact thumb reflex in areflexic Guillain Barré syndrome: A novel phenomenon

open access: yesAnnals of Indian Academy of Neurology, 2014
Introduction: Areflexia is one of the cardinal clinical features for the diagnosis of Guillain Barré syndrome. However, some patients may have sluggish proximal muscle stretch reflexes.
Karkal Ravishankar Naik   +2 more
doaj   +1 more source

Primary Cytomegalovirus Infection Causing Guillain-Barré Syndrome in a Living Renal Allograft Recipient

open access: yesCase Reports in Transplantation, 2017
Guillain-Barré Syndrome (GBS) is a common acute autoimmune polyneuropathy in adults. There have been few reported cases of Guillain-Barré Syndrome associated with active cytomegalovirus (CMV) infection in renal transplant recipients.
Massini Merzkani   +2 more
doaj   +1 more source

Plasmaferesis Sebagai Terapi Sindrom Guillain-Barre Berat pada Anak

open access: yesSari Pediatri, 2016
Plasmaferesis atau plasma exchange merupakan salah satu pilihan terapi bagi sindrom Guillain-Barre berat. Beberapa penelitian menunjukkan bahwa plasmaferesis dan imunoglobulin intravena (IVIg) sebagai terapi sindrom Guillain-Barre memiliki efektivitas ...
Vimaladewi Lukito   +3 more
doaj   +1 more source

Establishing an Apheresis Medicine Program in a Resource‐Constrained Setting: A 5‐Year Experience From Lagos, Nigeria

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola   +4 more
wiley   +1 more source

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

open access: yesAdvanced Science, EarlyView.
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami   +7 more
wiley   +1 more source

Evaluating discrepancies between high‐yield neuroscience conditions in preclerkship medical education and national clinical incidence

open access: yesAnatomical Sciences Education, EarlyView.
Abstract Medical education must balance foundational science with clinical relevance. Increasing emphasis on standardized assessments has led to prioritization of “high‐yield” conditions—those most likely to be assessed. Subsequently, educators and students often prioritize these conditions.
Kathryn Veazey, Oheneba Boadum
wiley   +1 more source

Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report

open access: yesJournal of Nobel Medical College, 2021
Guillain-Barre Syndrome has been reported as a rare side effect in the recipients of Johnson & Johnson®'s Janssen Ad26.COV2.S COVID-19 vaccine. We report a case of Guillain-Barre Syndrome in a 50 years old female following the administration of the ...
Sushmita Khanal, Sunil Babu Khanal
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy